Natera

    [td_text_with_title custom_title=”Company description”]Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. We operate a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California, and currently offer a host of proprietary genetic testing services.

    Natera’s goal is to change the way people – both providers and patients – respond to genetic diseases. We aim to do so by providing the most comprehensive and accurate genetic testing.[/td_text_with_title]

    [td_text_with_title custom_title=”Latest post”]
    182191

    Natera

    Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. We operate a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California, and currently offer a host of proprietary genetic testing services. Natera’s goal is to change the way people – both providers and patients – […]

    0 comments
    [/td_text_with_title][td_text_with_title custom_title=”From Wikipedia”]

    Natera (previously Gene Security Network) is a genetic testing company that operates a CLIA-certified laboratory in San Carlos, California.[1] The company specializes in analyzing microscopic quantities of DNA for reproductive health indications to provide preconception and prenatal genetic testing services primarily to OBGYN physicians and in vitro fertilization centers.[2]

    In early 2013, the company launched Panorama, a non-invasive prenatal test for pregnant women that screens for the most common chromosomal anomalies in a fetus as early as nine weeks of gestation.[3] Other services include tests for preimplantation genetic diagnosis (PGD) and miscarriage testing to determine the cause of the loss of the pregnancy.[4] A non-invasive paternity test based on Natera’s technology, was brought to market in August 2011 through a partnership with DNA Diagnostics Center (DDC), which holds a license to the technology in the United States.[5] In 2016, Dr. Susan Gross stepped aside as Natera's chief medical officer.

    Panorama Test

    Natera launched a non-invasive prenatal test (NIPT) in February 2013 called Panorama that uses an advanced bioinformatics-based algorithm to analyze the cell-free fetal DNA that is found in the mother’s blood. Panorama detects chromosome abnormalities, including Trisomy 21, the cause of Down syndrome, Trisomy 18, the cause of Edwards syndrome, Trisomy 13, the cause of Patau syndrome, sex chromosome abnormalities, triploidy and certain microdeletions as early as the first trimester of pregnancy.[6][7][8] A clinical study evaluating Natera’s NIPT is funded by the National Institutes of Health and is currently ongoing.

    Competition

    Companies also offering non-invasive prenatal genetic testing include Sequenom, Ariosa (Harmony Prenatal Test), Ravgen, and Verinata Health. Other companies and universities that are working towards developing non-invasive prenatal testing include Stanford University,[9] Fluidigm and Ikonisys.

    References

    source: https://en.wikipedia.org/wiki/Natera[/td_text_with_title]